Page last updated: 2024-10-25

ciprofloxacin and Sepsis

ciprofloxacin has been researched along with Sepsis in 184 studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.

Research Excerpts

ExcerptRelevanceReference
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL."9.12One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006)
"In the present study the effect of ciprofloxacin versus ceftazidime on concentrations of pro- and anti-inflammatory cytokines in the sera of patients with severe sepsis was evaluated."9.11Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. ( Bassaris, HP; Drosou, E; Gogos, CA; Lekkou, A; Marangos, MN; Skoutelis, A; Starakis, I, 2004)
"To compare meropenem with ciprofloxacin for treatment of gram-negative bacilli sepsis in penicillin-allergic patients in the intensive care unit (ICU) to determine if increased anaphylaxis risk with meropenem precluded its use when weighed against risks of inactive therapy with ciprofloxacin."8.87Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. ( Bolon, MK; Esterly, JS; Lee, TA; Postelnick, M; Reddy, P; Scheetz, MH, 2011)
"After appendectomy due to complicated acute appendicitis (CAA), there are some alternatives as antibiotic scheme: ciprofloxacin/metronidazole; as well as monoscheme based on carbapenems: ertapenem, meropenem, and imipenem."7.96Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population. ( Arevalo-Vidal, E; Baquerizo-Burgos, J; Bunces-Orellana, O; Bustos-Galarza, K; Ferrín-Viteri, M; Oleas, R; Puga-Tejada, M, 2020)
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs."7.80Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014)
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)."7.73In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005)
"Fourteen patients (6 women, 8 men) with thoracolumbar spondylitis were treated with anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia."7.73Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe? ( Iliopoulos, P; Korovessis, P; Koureas, G; Petsinis, G; Zacharatos, S, 2006)
"A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin."7.72A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003)
"To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis."7.71Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002)
"The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared."7.67Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987)
"The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared."7.67Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987)
"Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours."7.67Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989)
"In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone."5.51Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. ( Bosman, RJ; de Grooth, HJ; Driessen, R; Elbers, PWG; Fleuren, LM; Girbes, ARJ; Guo, T; Mathot, RAA; Roggeveen, LF; Swart, EL; Thoral, P; van den Bogaard, B; van Hest, RM, 2022)
"Salmonellosis is a relatively rare complication in kidney transplant recipients that cannot be clinically distinguished from other forms of enteritis."5.46Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient. ( Carminatti, M; Mendes, MM; Pinheiro, HS, 2017)
" Serious adverse reactions reported with ciprofloxacin are rare with an incidence of 0."5.35Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin. ( Ruxana, K; Upadya, GM, 2009)
" Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients."5.33Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005)
" Sixteen evaluable patients (three pharmacokinetic profiles) without renal dysfunction and with severe sepsis were studied."5.30Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ( Gous, AG; Hon, H; Lipman, J; Scribante, J; Tshukutsoane, S, 1998)
"The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats."5.28Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989)
"In this proof-of-principle intervention trial, 16 healthy young men received either no treatment or broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7 days, after which all were administered lipopolysaccharide intravenously to induce a transient sepsis-like syndrome."5.24Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. ( Belzer, C; Cranendonk, DR; de Vos, AF; de Vos, WM; Lankelma, JM; van der Poll, T; Wiersinga, WJ, 2017)
"Ciprofloxacin is a safe therapeutic option for newborns with sepsis produced by multiply resistant organisms."5.12Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. ( Ahmed, AS; Bhattacharya, M; Chowdhury, MA; Darmstadt, GL; Islam, M; Khan, NZ; Law, P; Muslima, H; Saha, SK, 2006)
"To evaluate whether 1 week of ciprofloxacin before percutaneous nephrolithotomy (PCNL) in patients with stones of > or = 20 mm or pelvicalyceal dilatation, reduces urosepsis, as we previously reported that such patients have four times the risk of urosepsis after PCNL."5.12One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. ( Mariappan, P; Moussa, SA; Smith, G; Tolley, DA, 2006)
"In the present study the effect of ciprofloxacin versus ceftazidime on concentrations of pro- and anti-inflammatory cytokines in the sera of patients with severe sepsis was evaluated."5.11Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. ( Bassaris, HP; Drosou, E; Gogos, CA; Lekkou, A; Marangos, MN; Skoutelis, A; Starakis, I, 2004)
"To compare meropenem with ciprofloxacin for treatment of gram-negative bacilli sepsis in penicillin-allergic patients in the intensive care unit (ICU) to determine if increased anaphylaxis risk with meropenem precluded its use when weighed against risks of inactive therapy with ciprofloxacin."4.87Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. ( Bolon, MK; Esterly, JS; Lee, TA; Postelnick, M; Reddy, P; Scheetz, MH, 2011)
"Rectal swab cultures identify patients with ciprofloxacin-resistant rectal flora who have an eight-fold risk of sepsis."3.96Effect of Augmented Antimicrobial Prophylaxis and Rectal Swab Culture-guided Targeted Prophylaxis on the Risk of Sepsis Following Transrectal Prostate Biopsy. ( Dall'Antonia, M; Eragat, M; Hadjipavlou, M; Hammadeh, MY; Kenny, C; Mulhem, W; Pantelidou, M; Wood, C, 2020)
"After appendectomy due to complicated acute appendicitis (CAA), there are some alternatives as antibiotic scheme: ciprofloxacin/metronidazole; as well as monoscheme based on carbapenems: ertapenem, meropenem, and imipenem."3.96Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population. ( Arevalo-Vidal, E; Baquerizo-Burgos, J; Bunces-Orellana, O; Bustos-Galarza, K; Ferrín-Viteri, M; Oleas, R; Puga-Tejada, M, 2020)
"There was a significant reduction in the incidence of sepsis after prostate biopsy using a combination of a ciprofloxacin-ceftriaxone antibiotic regimen and isopropyl alcohol needle washing."3.88Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin-Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing. ( Johnson-Mitchell, M; Neeb, AD; Simmons, MN, 2018)
" coli urosepsis was treated with ciprofloxacin for 2 weeks with excellent response."3.88IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient. ( Basic-Jukic, N; Coric, M; Kastelan, Z, 2018)
"In this prospective audit, patients were identified as having a low- or high-risk of sepsis based on a questionnaire about established risk factors: previous biopsy; recurrent urine infections; receiving ciprofloxacin in the 12 months prior; travel to South-East Asia or South America in the previous 6 months; or diabetes, immune system impairment or receipt of immunosuppressant drugs."3.80Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. ( Blackmore, T; Losco, G; Studd, R, 2014)
"To describe the use of ciprofloxacin and fluconazole for the treatment of sepsis in European neonatal intensive care units (NICUs) in order to better orient research aimed at acquiring essential knowledge in this critical area."3.79Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. ( Bonati, M; Choonara, I; Jacqz-Aigrain, E; Kaguelidou, F; Manzoni, P; Pandolfini, C; Sequi, M; Turner, MA, 2013)
"A ciprofloxacin (CFn)-loaded lipid emulsion was developed for treatment of intra-abdominal infections, especially sepsis."3.77An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis. ( Mishra, PR, 2011)
"Fourteen patients (6 women, 8 men) with thoracolumbar spondylitis were treated with anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia."3.73Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe? ( Iliopoulos, P; Korovessis, P; Koureas, G; Petsinis, G; Zacharatos, S, 2006)
"A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)."3.73In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005)
"24 preterm neonates with age < 28 days, who received intravenous ciprofloxacin 10 mg/kg/dose 12 hourly for clinical and/or culture proven sepsis, were enrolled."3.72Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ( Aggarwal, P; Dutta, S; Garg, SK; Narang, A, 2004)
"A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin."3.72A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene. ( Kuberski, T; Robinson, L; Schurgin, A, 2003)
" We isolated a strain of S choleraesuis that was resistant to ceftriaxone and ciprofloxacin from a patient with sepsis."3.72Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. ( Chia, JH; Chiu, CH; Chu, C; Lee, YS; Lin, TY; Ou, JT; Su, LH; Wu, TL, 2004)
"In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes."3.71Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002)
"To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis."3.71Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? ( Gous, AG; Hon, H; Lipman, J; Mathivha, LR; Pinder, M; Riera-Fanego, JF; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2002)
"Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours."3.67Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989)
"The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared."3.67Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987)
"The antibacterial activities of ciprofloxacin versus ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared."3.67Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro. ( Bakker-Woudenberg, IA; Michel, MF; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1987)
"Twenty-four episodes of fever in neutropenic patients with haematological malignancy were treated with ciprofloxacin."3.67Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. ( Farrell, ID; Geddes, AM; Leyland, MJ; Smith, GM, 1986)
"A steady increase in the incidence of septicemia after prostate biopsy in our unit between 2001 and 2005 prompted us to review our prophylactic antibiotic regimen."2.78Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. ( Al-Maghrebi, M; Anim, JT; Kehinde, EO; Sheikh, M, 2013)
"Oral ciprofloxacin is a cost-effective prophylactic agent for high-risk ERCP."2.69Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. ( Alveyn, CG; Davis, AJ; Kolios, G; Robertson, DA, 1998)
"Ora; ciprofloxacin was studied as a prophylactic antimicrobial agent in high- and low-risk patients undergoing endoscopic retrograde cholangiography."2.67Prevention of sepsis following endoscopic retrograde cholangiopancreatography. ( Alveyn, CG; Lowes, JA; Robertson, DA; Tillotson, G; Wright, R, 1991)
"Ciprofloxacin serum levels were measured after administration of the drug to 36 patients with septicemia (at least one positive blood culture) who were able to take oral medication."2.66Serum levels of ciprofloxacin after single oral doses in patients with septicemia. ( Auckenthaler, R; Bellido, F; D'Espine, M; Hirschel, B; Lew, D; Pechère, JC; Rohner, P, 1989)
"Ciprofloxacin displays largely concentration-dependent kill characteristics, but also exerts some time-dependent effects."2.43Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. ( Lipman, J; Roberts, JA, 2006)
"Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD)."1.72Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. ( Ahmadi, F; Garg, AX; Kim, RB; Knoll, GA; Muanda, FT; Silverman, MS; Sontrop, JM; Sood, MM; Weir, MA; Yoo, E, 2022)
"sepsis is defined as a systemic inflammatory host response syndrome (SIRS) to infection, commonly bacterial."1.72Aetiology, antimicrobial susceptibility and outcome of children with sepsis, admitted at Muhimbili National Hospital, Dar es Salaam. ( Assenga, EN; Godfrey, E; Majaliwa, E, 2022)
"Ciprofloxacin was the most prescribed oral antibiotic (53%)."1.72Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure. ( Gross, AE; Nakaranurack, C; Pradubkham, T; Suwanpimolkul, G, 2022)
"Bacteremia-induced sepsis is a leading cause of mortality in intensive care units."1.62Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. ( Alalaiwe, A; Dai, YS; Fang, JY; Liao, CC; Liu, FC; Yang, SC; Yu, HP, 2021)
"Post-URS sepsis was 7."1.56Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis. ( Amiel, GE; Badaan, S; Kastin, A; Kravtsov, A; Mullerad, M; Zisman, A, 2020)
"vulnificus septicemia during the study, and the 30-day survival rate was 39% (85/218)."1.51Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis. ( Darboe, KS; Jang, HC; Jung, SI; Kang, SJ; Kim, SE; Kim, UJ; Oh, TH; Park, KH; Shin, HY; Shin, SU, 2019)
"Sepsis is a life-threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide."1.48Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management. ( Gao, J; Wang, Z; Zhang, CY, 2018)
"Salmonellosis is a relatively rare complication in kidney transplant recipients that cannot be clinically distinguished from other forms of enteritis."1.46Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient. ( Carminatti, M; Mendes, MM; Pinheiro, HS, 2017)
"The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo."1.43Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli. ( Díaz-De-Alba, P; Docobo-Perez, F; Machuca, J; Ortiz, M; Pascual, Á; Recacha, E; Rodríguez-Martínez, JM, 2016)
"Ciprofloxacin resistance was found in 90."1.43The prevalence of urinary tract infection, or urosepsis following transrectal ultrasound-guided prostate biopsy in a subset of the Saudi population and patterns of susceptibility to flouroquinolones. ( Albqami, NM; AlKhateeb, SS; Alrabeeah, KA; AlShammari, NA; AlZughaibi, MA; Ghazwani, YG, 2016)
" Population pharmacokinetic analysis and Monte Carlo simulation was undertaken using Pmetrics."1.43Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ( Lefrant, JY; Lipman, J; Louart, B; Muller, L; Roberts, JA; Roger, C; Wallis, SC, 2016)
"Anthrax is a zoonotic occupational disease caused by Bacillus anthracis, a rod-shaped immobile aerobic gram-positive bacteria with spore."1.43A case report of inhalation anthrax acquired naturally. ( Azarkar, Z; Bidaki, MZ, 2016)
"Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0."1.42Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. ( Gupta, K; Lerner, L; Marino, K; Orlando, R; Parlee, A; Strymish, J, 2015)
"We report a case of C."1.42Successful Treatment of Chromobacterium violaceum Sepsis in a South Indian Adult. ( Madi, DR; Ramapuram, J; Shetty, AK; Vidyalakshmi, K, 2015)
"chelonae may be associated with nosocomial infections including catheter related sepsis, pneumonia etc."1.42Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host. ( Antony, SJ, 2015)
"Prostate cancer is the most common form of cancer in Danish men, and the incidence is rising."1.40Prophylactic antibiotics reduce sepsis after biopsy of the prostate. ( Hayatzaki, K; Menne, S; Nielsen, K, 2014)
"Methicillin resistance was seen in 10/46 (21."1.39Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. ( De Smet, B; Jacobs, JA; Kham, C; Koole, O; Lim, K; Lynen, L; Peetermans, WE; Phe, T; Veng, HC; Vlieghe, ER, 2013)
"We report a case of bacteremia and severe sepsis caused by S."1.36Mycotic abdominal aortic aneurysm due to Streptococcus suis: a case report. ( Arworn, S; Laohapensang, K; Rutherford, RB, 2010)
" Serious adverse reactions reported with ciprofloxacin are rare with an incidence of 0."1.35Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin. ( Ruxana, K; Upadya, GM, 2009)
"Ciprofloxacin-untreated rats exhibited a predominantly gram-negative polymicrobial sepsis."1.34Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. ( Fareed, J; Florian-Kujawski, M; Goto, M; Hammadeh, R; Hoppensteadt, D; Iqbal, O; Ravindranath, TM; Sayeed, MM, 2007)
" Ciprofloxacin pharmacokinetics in critically ill patients do not change over time, and intra-abdominal sepsis does not alter ciprofloxacin pharmacokinetic parameters to a greater degree than sepsis from other causes in critically ill patients."1.33Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. ( Gous, A; Hon, H; Lipman, J; Mathivha, R; Pinder, M; Scribante, J; Stass, H; Tshukutsoane, S; Verhoef, L, 2005)
"The majority of data evaluating Salmonella infections in sickle cell anemia (SCD) comes from studies performed in children."1.33Ceftriaxone-resistant Salmonella septicemia and osteomyelitis in sickle cell disease adults. ( Laber, DA; Morgan, JS, 2006)
"We conducted a case matched control study to observe the adverse effects of ciprofloxacin used in neonatal septicemia We enrolled 30 neonates with multidrug-resistant septicemia who were treated with intravenous ciprofloxacin for 14 days."1.32Safety profile of ciprofloxacin used for neonatal septicemia. ( Ambardekar, S; Chaudhari, S; Chinchwadkar, M; Kinare, A; Suryawanshi, P, 2004)
"Sepsis was induced by cecal ligation and puncture (CLP) in Swiss mice using an 18-gauge needle."1.32Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. ( Amâncio, RT; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; David, CM; Gomes, RN; Vianna, RC, 2004)
"Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features."1.32[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004)
" Sixteen evaluable patients (three pharmacokinetic profiles) without renal dysfunction and with severe sepsis were studied."1.30Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. ( Gous, AG; Hon, H; Lipman, J; Scribante, J; Tshukutsoane, S, 1998)
"Ciprofloxacin has been found to be effective in the treatment of multidrug-resistant Gram-negative infections in pediatric patients, including premature infants."1.30Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin. ( Khaneja, M; Kumar, A; Naprawa, J; Piecuch, S, 1999)
"A case of typhoid fever caused by a multiply antibiotic resistant strain of Salmonella typhi is reported."1.28Septicaemia caused by an imported strain of multiply antibiotic resistant Salmonella typhi successfully treated with ciprofloxacin. ( Bhana, R; Coovadia, Y; Seebaran, A, 1990)
"Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n = 14), the MIC90 values being 0."1.28Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. ( Bale, MJ; Doebbeling, BN; Pfaller, MA; Wenzel, RP, 1990)
"Amikacin was bacteriostatic, with an MIC of 4."1.28Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. ( Inderlied, CB; Kolonoski, PT; Wu, M; Young, LS, 1989)
"A case of septicemia caused by MRSA is reported with discussion on its prophylaxis."1.28[A case report of septicemia caused by methicillin cephem resistant Staphylococcus aureus (MRSA)]. ( Arakawa, S; Den, S; Gohji, K; Ka, S; Kamidono, S; Maeda, H; Matsui, T; Matsumoto, O; Okada, H; Takagi, S, 1989)
"In ciprofloxacin-treated patients the flora were almost completely ciprofloxacin-resistant, whereas in the control groups resistant flora were detected only occasionally."1.28Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. ( Huovinen, P; Kotilainen, P; Nikoskelainen, J, 1990)
"Ciprofloxacin was withdrawn from use in the unit and daily bathing with chlorhexidine gluconate solution started."1.28Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. ( Burnie, JP; Hartley, JW; Lee, W; Oppenheim, BA, 1989)
"The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimental Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats."1.28Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. ( Bakker-Woudenberg, IA; Michel, BM; Roosendaal, R; van den Berghe-van Raffe, M; Vink-van den Berg, JC, 1989)
"Ciprofloxacin treatment was effective on both occasions."1.28Successful treatment of Bacillus cereus infection with ciprofloxacin. ( Gascoigne, AD; Gibson, GJ; Gould, K; Richards, J, 1991)
"Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls."1.28Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991)
"Ciprofloxacin is an effective and safe therapeutic alternative in many tissue infections caused by susceptible microorganisms."1.27Open, prospective study of the clinical efficacy of ciprofloxacin. ( Bran, JL; Garcia, JF; Mejia, CR; Ramirez, CA, 1985)
" This finding was likely due to changes in the pharmacokinetics of the drug with multiple dosing and in infected versus uninfected rabbits."1.27Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. ( Barriere, SL; Fekety, R; Kaatz, GW; Schaberg, DR, 1987)

Research

Studies (184)

TimeframeStudies, this research(%)All Research%
pre-199034 (18.48)18.7374
1990's26 (14.13)18.2507
2000's37 (20.11)29.6817
2010's67 (36.41)24.3611
2020's20 (10.87)2.80

Authors

AuthorsStudies
Cecchetti, V1
Fravolini, A1
Lorenzini, MC1
Tabarrini, O1
Terni, P1
Xin, T1
Gerasyuto, AI1
Arnold, MA1
Wang, J1
Chen, G1
Zhang, X1
Smith, S1
Woll, MG1
Baird, J1
Zhang, N1
Almstead, NG1
Narasimhan, J1
Peddi, S1
Dumble, M1
Sheedy, J1
Weetall, M1
Branstrom, AA1
Prasad, JVN1
Karp, GM1
Mohammed, JM1
Sajana, TM1
Raj, R1
Rachana, BA1
Paul, G1
Pillai, PR1
Rodríguez, I1
Figueiredo, AS1
Sousa, M1
Aracil-Gisbert, S1
Fernández-de-Bobadilla, MD1
Lanza, VF1
Rodríguez, C1
Zamora, J1
Loza, E1
Mingo, P1
Brooks, CJ1
Cantón, R1
Baquero, F1
Coque, TM1
Coombs, GW1
Daley, DA1
Yee, NWT1
Shoby, P1
Mowlaboccus, S1
Al-Faifi, J1
Ibrahim, ME1
Muanda, FT1
Sood, MM1
Weir, MA1
Sontrop, JM1
Ahmadi, F1
Yoo, E1
Kim, RB1
Silverman, MS1
Knoll, GA1
Garg, AX1
Roggeveen, LF1
Guo, T1
Fleuren, LM1
Driessen, R1
Thoral, P1
van Hest, RM1
Mathot, RAA1
Swart, EL1
de Grooth, HJ1
van den Bogaard, B1
Girbes, ARJ1
Bosman, RJ1
Elbers, PWG1
Pradubkham, T1
Suwanpimolkul, G1
Gross, AE1
Nakaranurack, C1
Godfrey, E1
Majaliwa, E1
Assenga, EN1
Tian, C1
Xing, M1
Zhao, Y1
Fan, X1
Bai, Y1
Fu, L1
Wang, S1
Wang, DY1
Yang, G1
Zhang, XX1
van der Mei, HC1
Ren, Y1
Busscher, HJ1
Shi, L1
Nielsen, RT1
Andersen, CØ1
Schønheyder, HC1
Petersen, JH1
Knudsen, JD1
Jarløv, JO1
Norredam, M1
Islam, MA1
Alam, SM1
Reza, AM1
Atassi, G1
Medernach, R1
Scheetz, M1
Nozick, S1
Rhodes, NJ1
Murphy-Belcaster, M1
Murphy, KR1
Alisoltani, A1
Ozer, EA1
Hauser, AR1
Zisman, A1
Badaan, S1
Kastin, A1
Kravtsov, A1
Amiel, GE1
Mullerad, M1
Wolf, S1
Frosch, T2
Popp, J1
Pletz, MW1
Hadjipavlou, M1
Eragat, M1
Kenny, C1
Pantelidou, M1
Mulhem, W1
Wood, C1
Dall'Antonia, M1
Hammadeh, MY1
Forde, C1
McMullan, R1
Clarke, M1
Wilson, RH1
Plummer, R1
Grayson, M1
McDowell, C1
Agus, A1
Doran, A1
McAuley, DF1
Thomas, AL1
Barnes, RA1
Adams, R1
Chau, I1
Coyle, V1
Bunces-Orellana, O1
Arevalo-Vidal, E1
Bustos-Galarza, K1
Ferrín-Viteri, M1
Oleas, R1
Baquerizo-Burgos, J1
Puga-Tejada, M1
Mazumder, R1
Sadique, T1
Sen, D1
Mozumder, P1
Rahman, T1
Chowdhury, A1
Halim, F1
Akter, N1
Ahmed, D1
Barnawi, AI1
Kordy, FN1
Almuwallad, OK1
Kassarah, KA1
Liao, CC1
Yu, HP1
Yang, SC1
Alalaiwe, A1
Dai, YS1
Liu, FC1
Fang, JY1
Mendes, MM1
Carminatti, M1
Pinheiro, HS1
Zembower, TR1
Maxwell, KM1
Nadler, RB1
Cashy, J1
Scheetz, MH2
Qi, C1
Schaeffer, AJ1
Goodlet, KJ1
Nicolau, DP1
Nailor, MD1
Rossi, O1
Dybowski, R1
Maskell, DJ1
Grant, AJ1
Restif, O1
Mastroeni, P1
Trinh, SA1
Gavin, HE1
Satchell, KJF1
Bloomfield, M1
Blackmore, T2
Qi, DZ1
Lehman, K1
Dewan, K2
Kirimanjeswara, G2
Raman, JD3
Roberts, MJ1
Scott, S1
Harris, PN1
Naber, K1
Wagenlehner, FME1
Doi, SAR1
Simmons, MN1
Neeb, AD1
Johnson-Mitchell, M1
Atala, A2
Elshal, AM1
Atwa, AM1
El-Nahas, AR1
El-Ghar, MA1
Gaber, A1
Elsawy, E1
Hashem, A1
Farag, Y1
Farg, H1
Elsorougy, A1
Fouda, M1
Nabeeh, H1
Mosbah, A1
Basic-Jukic, N1
Coric, M1
Kastelan, Z1
Zhang, CY1
Gao, J1
Wang, Z1
Fadel, MG1
Louis, C1
Tay, A1
Bolgeri, M1
Sewell, J1
Chow, K1
De Sousa, A1
Sapre, N1
Norris, B1
Namdarian, B1
Sinickas, V1
Huang, JG1
Anderson, P1
Kim, SE3
Shin, SU1
Oh, TH1
Kim, UJ2
Darboe, KS2
Kang, SJ3
Jang, HC3
Jung, SI3
Shin, HY1
Park, KH4
Kim, HK2
Choi, SM2
Yu, Y1
Kang, G1
Kim, YR2
Rhee, JH2
Lipton, G1
Tikka, T1
Soulsby, H1
Keh, S1
Vlieghe, ER1
Phe, T1
De Smet, B1
Veng, HC1
Kham, C1
Lim, K1
Koole, O1
Lynen, L1
Peetermans, WE1
Jacobs, JA1
Gaylis, F1
Fink, L1
Eshwara, VK1
Sasi, A1
Munim, F1
Purkayastha, J1
Lewis, LE1
Mukhopadhyay, C1
Ozgur, BC1
Sarici, H1
Doluoglu, OG1
Telli, O1
Eroglu, M1
Yeh, TC1
Liu, HC1
Hou, JY1
Chen, KH1
Huang, TH1
Chang, CY1
Liang, DC1
Jain, V1
Shukla, P1
Pal, R1
Mishra, PR2
Losco, G1
Studd, R1
Ryu, PY1
Lee, TH1
Choy, HE1
Hanna, MY1
Tremlett, C1
Josan, G1
Eltom, A1
Mills, R1
Rochester, M1
Livermore, DM1
Heidari Bateni, Z1
Shahrokh, H1
Salimi, H1
Safari, H1
Tabatabai, M1
Saedi, D1
Hayatzaki, K1
Menne, S1
Nielsen, K1
Rossmann, FS1
Racek, T1
Wobser, D1
Puchalka, J1
Rabener, EM1
Reiger, M1
Hendrickx, AP1
Diederich, AK1
Jung, K1
Klein, C1
Huebner, J1
Liss, MA1
Kim, W1
Moskowitz, D1
Szabo, RJ1
Antony, SJ1
Madi, DR1
Vidyalakshmi, K1
Ramapuram, J1
Shetty, AK1
Marino, K1
Parlee, A1
Orlando, R2
Lerner, L1
Strymish, J1
Gupta, K1
Wagenlehner, F1
Lehman, KK1
Ahn, JY1
Min, JK1
Kim, MH1
Moon, SY1
Lee, MS1
Son, JS1
Azarkar, Z1
Bidaki, MZ1
Roger, C1
Wallis, SC1
Louart, B1
Lefrant, JY1
Lipman, J5
Muller, L1
Roberts, JA2
Nazir, S1
Brown, K1
Shin, AK1
Donato, AA1
Lankelma, JM1
Cranendonk, DR1
Belzer, C1
de Vos, AF1
de Vos, WM1
van der Poll, T1
Wiersinga, WJ1
AlKhateeb, SS1
AlShammari, NA1
AlZughaibi, MA1
Ghazwani, YG1
Alrabeeah, KA1
Albqami, NM1
Machuca, J1
Ortiz, M1
Recacha, E1
Díaz-De-Alba, P1
Docobo-Perez, F2
Rodríguez-Martínez, JM1
Pascual, Á1
Kesler, KA1
Langdorf, MI1
Burns, MJ1
Vrtis, MC1
Kim, DM1
Cho, HS1
Kang, JI1
Kim, HS1
Park, CY1
Farhat, H1
Chachaty, E1
Antoun, S1
Nitenberg, G1
Zahar, JR1
Moniri, R1
Dastehgoli, K1
Laohapensang, K1
Rutherford, RB1
Arworn, S1
Upadya, GM1
Ruxana, K1
Aygencel, G1
Dizbay, M1
Loron, G1
Olivier, P1
See, H1
Le Saché, N1
Angulo, L1
Biran, V1
Brunelle, N1
Besson-Lescure, B1
Kitzis, MD1
Pansiot, J1
Bingen, E1
Gressens, P1
Bonacorsi, S1
Baud, O1
Bolon, MK1
Esterly, JS1
Reddy, P1
Postelnick, M1
Lee, TA1
Smani, Y1
López-Rojas, R1
Domínguez-Herrera, J1
Martí, S1
Vila, J1
Pachón, J1
Pinkhasov, GI1
Lin, YK1
Palmerola, R1
Smith, P1
Mahon, F1
Kaag, MG1
Dagen, JE1
Harpster, LE1
Reese, CT1
Issaoui, S1
Maoulainine, FM1
Elidrissi, NS1
Sorra, N1
Chabaa, L1
Aboussad, A1
Carignan, A1
Roussy, JF1
Lapointe, V1
Valiquette, L1
Sabbagh, R1
Pépin, J1
Marra, A1
Lamb, L1
Medina, I1
George, D1
Gibson, G1
Hardink, J1
Rugg, J1
Van Deusen, J1
O'Donnell, JP1
Kehinde, EO1
Al-Maghrebi, M1
Sheikh, M1
Anim, JT1
Pandolfini, C2
Kaguelidou, F1
Sequi, M1
Jacqz-Aigrain, E1
Choonara, I1
Turner, MA1
Manzoni, P1
Bonati, M1
Coutinho, AS1
de Morais, OO1
Gomes, CM1
de Oliveira Carneiro da Motta, J1
Gollard, R1
Rahman, S1
Ratnasabapathy, R1
Breda, SA1
Guzmán, ML1
Confalonieri, A1
González, C1
Sparo, M1
Manzo, RH1
Bruni, SS1
Olivera, ME1
Marco, S1
Paolo, M1
Maurizio, B1
Demirtas, A1
Yildirim, YE1
Sofikerim, M2
Kaya, EG1
Akinsal, EC1
Tombul, ST1
Ekmekcioglu, O1
Gulmez, I2
Bakker-Woudenberg, IA4
ten Kate, MT1
Guo, L1
Working, P1
Mouton, JW1
Rosenthal, EJ1
Kuberski, T1
Robinson, L1
Schurgin, A1
Fendukly, F1
Karlsson, I1
Hanson, HS1
Kronvall, G1
Dornbusch, K1
Bagia, JS1
Hall, R1
Vianna, RC1
Gomes, RN1
Bozza, FA1
Amâncio, RT1
Bozza, PT1
David, CM1
Castro-Faria-Neto, HC1
Chiu, CH1
Su, LH1
Chu, C1
Chia, JH1
Wu, TL1
Lin, TY1
Lee, YS1
Ou, JT1
Gogos, CA1
Skoutelis, A1
Lekkou, A1
Drosou, E1
Starakis, I1
Marangos, MN1
Bassaris, HP1
Perera, S1
Palasuntheram, C1
Aggarwal, P1
Dutta, S1
Garg, SK1
Narang, A1
Obara, Y1
Nagai, T1
Mori, M1
Ohmine, K1
Toshima, M1
Komatsu, N1
Ozawa, K1
Chaudhari, S1
Suryawanshi, P1
Ambardekar, S1
Chinchwadkar, M1
Kinare, A1
Ray, P1
Sharma, J1
Marak, RS1
Singhi, S1
Taneja, N1
Garg, RK1
Sharma, M1
Alkorta, M1
Giménez, MJ1
Vicente, D1
Aguilar, L1
Pérez-Trallero, E1
Gous, A1
Scribante, J3
Tshukutsoane, S3
Hon, H3
Pinder, M2
Mathivha, R1
Verhoef, L2
Stass, H2
Engelhardt, D1
Ruckdeschel, G1
Morris, P1
O'Sullivan, E1
Choo, M1
Barry, C1
Thompson, CJ1
Korovessis, P1
Petsinis, G1
Koureas, G1
Iliopoulos, P1
Zacharatos, S1
Morgan, JS1
Laber, DA1
Mariappan, P1
Smith, G2
Moussa, SA1
Tolley, DA1
Ahmed, AS1
Khan, NZ1
Saha, SK1
Chowdhury, MA1
Muslima, H1
Law, P1
Islam, M1
Bhattacharya, M1
Darmstadt, GL1
Karacagil, M1
Corbin, A1
Delatte, C1
Besson, S1
Guidry, A1
Hoffmann, AH1
Monier, P1
Nathaniel, R1
Ravindranath, TM1
Goto, M1
Iqbal, O1
Florian-Kujawski, M1
Hoppensteadt, D1
Hammadeh, R1
Sayeed, MM1
Fareed, J1
Begum, SA1
Lutfor, AB1
Mollah, AH1
Hasan, MK1
Ahmed, S1
Akhter, M1
Salauddin, NM1
van Hees, BC1
de Ruiter, E1
Wiltink, EH1
de Jongh, BM1
Tersmette, M1
Rossi, P1
Persson, B1
Boels, PJ1
Arner, A1
Weitzberg, E1
Oldner, A1
Klesel, N1
Geweniger, KH1
Koletzki, P1
Isert, D1
Limbert, M1
Markus, A1
Riess, G1
Schramm, H1
Iyer, P1
Burnett, RJ1
Haverstock, DC1
Dellinger, EP1
Reinhart, HH1
Bohnen, JM1
Rotstein, OD1
Vogel, SB1
Solomkin, JS1
Perras, B1
Kreft, B1
Wiedemann, G1
Bloch, KC1
Nadarajah, R1
Jacobs, R1
Galley, HF1
Nelson, SJ1
Dubbels, AM1
Webster, NR1
Mulder, JG1
Kosterink, JG1
Degener, JE1
Davis, AJ1
Kolios, G1
Alveyn, CG2
Robertson, DA2
Newcomb, D1
Bolgos, G1
Green, L1
Remick, DG1
Gous, AG2
Opal, SM1
Jhung, JW1
Keith, JC1
Palardy, JE1
Parejo, NA1
Young, LD1
Bhattacharjee, A1
Khaneja, M1
Naprawa, J1
Kumar, A1
Piecuch, S1
Gilad, J1
Borer, A1
Peled, N1
Riesenberg, K1
Tager, S1
Appelbaum, A1
Schlaeffer, F1
Moore, CC1
Lane, JE1
Stephens, JL1
Mastrullo, L1
De Blasi, D1
Boffa, ML1
Zorzato, G1
Miraglia, E1
Mathivha, LR1
Riera-Fanego, JF1
Ghadage, DP1
Bal, AM1
Nelson, MR1
Shanson, DC1
Hawkins, DA1
Gazzard, BG1
Wright, R1
Lowes, JA1
Tillotson, G1
Roach, MB1
Figueroa, TE1
McBride, D1
George, WJ1
Neal, DE1
Gascoigne, AD1
Richards, J1
Gould, K1
Gibson, GJ1
Shah, PM1
Azoulay-Dupuis, E1
Bedos, JP1
Vallée, E1
Hardy, DJ1
Swanson, RN1
Pocidalo, JJ1
Coovadia, Y1
Seebaran, A1
Bhana, R1
Oliver, RM1
Waller, DG1
Rubin, CM1
Booth, LV1
Doebbeling, BN1
Pfaller, MA1
Bale, MJ1
Wenzel, RP1
Choo, PW1
Gantz, NM1
Lode, H1
Wiley, E1
Olschewski, P1
Sievers, H1
Wintermantel, M1
Baetz, R1
Lebahn, K1
Reinke, M1
Wagner, J1
Borner, K1
Warren, RE1
Wimperis, JZ1
Baglin, TP1
Constantine, CE1
Marcus, R1
Kotilainen, P1
Nikoskelainen, J1
Huovinen, P1
Dekker, AW1
Rozenberg-Arska, M1
Verdonck, LF1
Grabe, M1
Forsgren, A1
Björk, T1
Pedro-Botet Montoya, J1
Tomás Vecina, S1
Soriano Giménez, JC1
Rubiés-Prat, J1
Oppenheim, BA1
Hartley, JW1
Lee, W1
Burnie, JP1
Díaz-Tejeiro, R1
Díez, J1
Maduell, F1
Esparza, N1
Errasti, P1
Purroy, A1
Roosendaal, R3
van den Berghe-van Raffe, M3
Vink-van den Berg, JC3
Michel, BM1
Gangji, D1
Jacobs, F1
de Jonckheer, J1
Coppens, L1
Serruys, E1
Hanotte, F1
Motte, S1
Thys, JP1
Bouza, E1
Díaz-López, MD1
Bernaldo de Quirós, JC1
Rodríguez-Créixems, M1
Greenberg, RN1
Wilson, KM1
Brusca, PA1
Brown, AE1
Bannon, MJ1
Stutchfield, PR1
Weindling, AM1
Damjanovic, V1
Weers-Pothoff, G1
Novakova, IR1
Donnelly, JP1
Muytjens, HL1
D'Espine, M1
Bellido, F1
Pechère, JC1
Auckenthaler, R1
Rohner, P1
Lew, D1
Hirschel, B1
Jacobson, MA1
Hahn, SM1
Gerberding, JL1
Lee, B1
Sande, MA1
Inderlied, CB1
Kolonoski, PT1
Wu, M1
Young, LS1
Arakawa, S1
Takagi, S1
Matsui, T1
Maeda, H1
Ka, S1
Den, S1
Gohji, K1
Okada, H1
Matsumoto, O1
Kamidono, S1
Cooper, B1
Lawlor, M1
Ramirez, CA1
Bran, JL1
Mejia, CR1
Garcia, JF1
Patton, WN1
Smith, GM2
Leyland, MJ2
Geddes, AM2
Zumla, A1
Lewis, D1
Brown, J1
Bendig, JW1
Kyle, PW1
Giangrande, PL1
Samson, DM1
Azadian, BS1
Zervos, MJ1
Bacon, AE1
Patterson, JE1
Schaberg, DR2
Kauffman, CA1
Daikos, GL1
Kathpalia, SB1
Lolans, VT1
Jackson, GG1
Fosslien, E1
Trautmann, M1
Brückner, O1
Marre, R1
Hahn, H1
Michel, MF2
Newland, AC1
Wood, ME1
Rolston, KV1
Ho, DH1
LeBlanc, B1
Bodey, GP1
Farrell, ID1
Connolly, MJ1
Snow, MH1
Ingham, HR1
Kaatz, GW1
Barriere, SL1
Fekety, R1
Dibble, JB1
Acomb, C1
Campbell, L1
White, LO1
Brownjohn, AM1
Weinstein, MP1
Masur, H1
Tuazon, C1
Gill, V1
Grimes, G1
Baird, B1
Fauci, AS1
Lane, HC1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy[NCT03879486]1,257 participants (Actual)Interventional2017-05-31Completed
Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)[NCT01659866]Phase 4563 participants (Actual)Interventional2012-08-31Completed
The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia[NCT02127749]16 participants (Actual)Interventional2014-06-30Completed
Neutrophil and Lymphocyte Counts and the Neutrophil-to-lymphocyte Ratio as a Predictor of Fever Following Percutaneous Nephrolithotomy in Patients Without Risk Factors[NCT03774940]519 participants (Actual)Interventional2005-01-01Completed
The Preventive Urinary Tract Infection Role of One Week Solutions of Antimicrobial Application Before Minimally Invasive Upper Tract Lithotomy[NCT02789579]Early Phase 1150 participants (Anticipated)Interventional2016-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Post-biopsy Infection.

To measure and compare the rates of infection following TRUSP in subjects with and without CR-GNB. This measure is number of participants with post-biopsy infection. (NCT01659866)
Timeframe: 30 days post-biopsy

Interventionparticipants (Number)
Cipro-susceptible6
Cipro-resistant3

Reviews

8 reviews available for ciprofloxacin and Sepsis

ArticleYear
Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis.
    World journal of urology, 2018, Volume: 36, Issue:3

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy, Large-Core Needle; Ciproflo

2018
Prevertebral neck abscess with
    BMJ case reports, 2019, Jul-24, Volume: 12, Issue:7

    Topics: Abscess; Ceftriaxone; Ciprofloxacin; Diabetes Mellitus, Type 2; Drainage; Humans; Male; Metronidazol

2019
Is your patient taking the right antimicrobial?
    The American journal of nursing, 2008, Volume: 108, Issue:6

    Topics: Adult; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Causality; Ciprofloxacin

2008
Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model.
    Pharmacotherapy, 2011, Volume: 31, Issue:5

    Topics: Anaphylaxis; Anti-Bacterial Agents; Ciprofloxacin; Decision Trees; Drug Hypersensitivity; Gram-Negat

2011
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Clinical pharmacokinetics, 2006, Volume: 45, Issue:8

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; beta-Lactams; Ciprofloxacin; Critical Care; Drug A

2006
Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review.
    Medicine, 1997, Volume: 76, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Breast Neoplasms; Ciprofloxacin; Dr

1997
Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review.
    Scandinavian journal of infectious diseases, 2000, Volume: 32, Issue:1

    Topics: Adult; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Cross Infection; Female; Humans; Microbial S

2000
Prevention of infection by ciprofloxacin in neutropenia.
    The Journal of antimicrobial chemotherapy, 1990, Volume: 26 Suppl F

    Topics: Ciprofloxacin; Erythromycin; Feces; Gram-Negative Bacteria; Humans; Neutropenia; Sepsis; Staphylococ

1990

Trials

18 trials available for ciprofloxacin and Sepsis

ArticleYear
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
    Critical care (London, England), 2022, 09-05, Volume: 26, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Critical Illness; Humans; Pandemics; Sepsis;

2022
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
    Trials, 2020, May-27, Volume: 21, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; An

2020
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
    BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac

2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
    BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac

2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
    BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac

2017
Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial.
    BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Ciprofloxac

2017
Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.
    World journal of urology, 2018, Volume: 36, Issue:11

    Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Large-Core Needle; Bloo

2018
Single-dose versus multiple-dose ciprofloxacin plus metronidazole prophylaxis in transrectal ultrasound-guided biopsy of the prostate: a randomized controlled trial.
    Acta medica Iranica, 2014, Volume: 52, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial

2014
Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study.
    Gut, 2017, Volume: 66, Issue:9

    Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Monitoring; Endotoxemia; Escherichia coli; Gastroi

2017
Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate.
    The Journal of urology, 2013, Volume: 189, Issue:3

    Topics: Aged; Aged, 80 and over; Amikacin; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Ci

2013
Comparison of infection and urosepsis rates of ciprofloxacin and ceftriaxone prophylaxis before percutaneous nephrolithotomy: a prospective and randomised study.
    TheScientificWorldJournal, 2012, Volume: 2012

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftriaxone; Ciproflo

2012
Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:8

    Topics: Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cytokines; Female; G

2004
One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study.
    BJU international, 2006, Volume: 98, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Dilatation, Pathologic; Female

2006
Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development.
    The Pediatric infectious disease journal, 2006, Volume: 25, Issue:12

    Topics: Bangladesh; Child Development; Ciprofloxacin; Female; Follow-Up Studies; Humans; Infant; Infant, New

2006
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
    Surgery, 1995, Volume: 118, Issue:4

    Topics: Abscess; Adult; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Double-Blind Method; Drug Resistan

1995
Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients.
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bile; C

1998
Prevention of sepsis following endoscopic retrograde cholangiopancreatography.
    The Journal of hospital infection, 1991, Volume: 19 Suppl C

    Topics: Administration, Oral; Cefazolin; Cholangiopancreatography, Endoscopic Retrograde; Ciprofloxacin; Dou

1991
Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy.
    Urology, 1991, Volume: 38, Issue:1

    Topics: Aged; Biopsy, Needle; Ciprofloxacin; Follow-Up Studies; Gentamicins; Humans; Male; Prostate; Rectum;

1991
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
    Scandinavian journal of infectious diseases. Supplementum, 1990, Volume: 68

    Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination

1990
Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of gram-negative septicemia.
    The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A

    Topics: Administration, Oral; Aged; Ciprofloxacin; Drug Administration Schedule; Gram-Negative Bacteria; Hum

1989
Serum levels of ciprofloxacin after single oral doses in patients with septicemia.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989, Volume: 8, Issue:12

    Topics: Administration, Oral; Adult; Ciprofloxacin; Half-Life; Humans; Random Allocation; Sepsis; Time Facto

1989

Other Studies

158 other studies available for ciprofloxacin and Sepsis

ArticleYear
Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones.
    Journal of medicinal chemistry, 1996, Jan-19, Volume: 39, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Female; Magnetic Resonance Spectroscopy; Male; Mice; Quinolones; Sep

1996
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
    Journal of medicinal chemistry, 2018, 05-24, Volume: 61, Issue:10

    Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multip

2018
'The Violet Killer'-Successful Treatment of an Infant with Chromobacterium violaceum Sepsis.
    Journal of tropical pediatrics, 2021, 08-27, Volume: 67, Issue:4

    Topics: Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Gram-Negative Bacterial Infections; Humans; I

2021
A 21-Year Survey of Escherichia coli from Bloodstream Infections (BSI) in a Tertiary Hospital Reveals How Community-Hospital Dynamics of B2 Phylogroup Clones Influence Local BSI Rates.
    mSphere, 2021, 12-22, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Ciproflo

2021
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
    Communicable diseases intelligence (2018), 2022, Apr-26, Volume: 46

    Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe

2022
Congenital brucellosis associated with subsequent Klebsiella pneumoniae co-infection in a premature neonate: A rare case report.
    Journal of infection and public health, 2022, Volume: 15, Issue:5

    Topics: Amikacin; Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Coinfection; Female; Gentamicins; Human

2022
Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
    JAMA network open, 2022, 08-01, Volume: 5, Issue:8

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Death, Sudden, Cardia

2022
Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure.
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Gram-Negative Bacterial Infections; HIV Infections

2022
Aetiology, antimicrobial susceptibility and outcome of children with sepsis, admitted at Muhimbili National Hospital, Dar es Salaam.
    The Pan African medical journal, 2022, Volume: 42

    Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Inf

2022
Whole genome sequencing of OXA-232-producing
    Frontiers in cellular and infection microbiology, 2022, Volume: 12

    Topics: Amikacin; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Chromosomes; Ciprof

2022
Proton-mediated burst of dual-drug loaded liposomes for biofilm dispersal and bacterial killing.
    Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 352

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Bromelains; Ciprofloxacin; Lipids; Liposomes; Mice; Microb

2022
Differences in the distribution of pathogens and antimicrobial resistance in bloodstream infections in migrants compared with non-migrants in Denmark.
    Infectious diseases (London, England), 2023, Volume: 55, Issue:3

    Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Community-Acquired Infections; Denmark; Drug Resis

2023
Urosepsis and Bacteriuria in Patients Undergoing TRUS-Guided Prostate Biopsy.
    Mymensingh medical journal : MMJ, 2023, Volume: 32, Issue:2

    Topics: Anti-Bacterial Agents; Bacteriuria; Bangladesh; Biopsy; Ciprofloxacin; Cross-Sectional Studies; Esch

2023
Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital.
    Microbiology spectrum, 2023, 06-15, Volume: 11, Issue:3

    Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Genomic

2023
Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis.
    Urologia internationalis, 2020, Volume: 104, Issue:1-2

    Topics: Administration, Oral; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprof

2020
Highly Sensitive Detection of the Antibiotic Ciprofloxacin by Means of Fiber Enhanced Raman Spectroscopy.
    Molecules (Basel, Switzerland), 2019, Dec-10, Volume: 24, Issue:24

    Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Monitoring; Humans; Sepsis; Spectrum Analysis, Raman

2019
Effect of Augmented Antimicrobial Prophylaxis and Rectal Swab Culture-guided Targeted Prophylaxis on the Risk of Sepsis Following Transrectal Prostate Biopsy.
    European urology focus, 2020, 01-15, Volume: 6, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteriological Techniques; Biopsy; Ciprofloxacin; Ge

2020
Carbapenems versus ciprofloxacin/metronidazole for decreasing complications and hospital stay following complicated acute appendicitis surgery: A prospective cohort in an Ecuadorian population.
    Cirugia y cirujanos, 2020, Volume: 88, Issue:3

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Appendectomy; Appendicitis; Carbapenems;

2020
Agricultural Injury-Associated
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; Chromobacterium; Ciprofloxacin; Farmers;

2020
Early neonatal sepsis and meningitis caused by Elizabethkingia meningoseptica in Saudi Arabia.
    Saudi medical journal, 2020, Volume: 41, Issue:7

    Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female;

2020
Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.
    Journal of nanobiotechnology, 2021, Feb-15, Volume: 19, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Ciprofloxacin; Disease Models,

2021
Severe sepsis from a Ciprofloxacin resistant salmonellosis in a kidney transplant recipient.
    Jornal brasileiro de nefrologia, 2017, Volume: 39, Issue:1

    Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Kidney Transplantati

2017
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug

2017
Within-host spatiotemporal dynamics of systemic Salmonella infection during and after antimicrobial treatment.
    The Journal of antimicrobial chemotherapy, 2017, Dec-01, Volume: 72, Issue:12

    Topics: Ampicillin; Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Ciprofloxacin;

2017
Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Animals; Anti-Bacterial Agents; Cefepime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Doxycycline; D

2017
Prophylactic ciprofloxacin for prostate biopsy: a losing bet?
    Nature reviews. Urology, 2017, Volume: 14, Issue:11

    Topics: Anti-Bacterial Agents; Biopsy; Carbapenems; Ciprofloxacin; Humans; Male; Prostate; Sepsis

2017
Preoperative urine culture is unnecessary in asymptomatic men prior to prostate needle biopsy.
    International urology and nephrology, 2018, Volume: 50, Issue:1

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Asymptomatic Diseases; Bacteriuria; Biopsy, Nee

2018
Reduced Risk of Sepsis after Prostate Biopsy Using a Cephalosporin-Fluoroquinolone Antibiotic Regimen and Isopropyl Alcohol Needle Washing.
    Urology, 2018, Volume: 115

    Topics: 2-Propanol; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Body Mass Index; Ceftriaxon

2018
Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
    The Journal of urology, 2017, Volume: 197, Issue:5

    Topics: Animals; Bacteria; Ciprofloxacin; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rat

2017
IgA-dominant extracapillary proliferative glomerulonephritis following Escherichia coli sepsis in a renal transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:5

    Topics: Aged; Allografts; Biopsy; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Glomerulonep

2018
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management.
    Advanced materials (Deerfield Beach, Fla.), 2018, Volume: 30, Issue:43

    Topics: Amides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Proteins;

2018
Obstructive urosepsis secondary to ureteric herniation into the sciatic foramen.
    BMJ case reports, 2018, Sep-27, Volume: 2018

    Topics: Abdominal Pain; Acute Disease; Aged; Anti-Bacterial Agents; Ciprofloxacin; Female; Hernia; Humans; H

2018
Extended-spectrum β-lactamase in the rectal flora of patients undergoing transrectal prostate biopsy: a study of the prevalence in a major metropolitan hospital.
    BJU international, 2019, Volume: 123 Suppl 5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactamases; Cipr

2019
Outcomes of Third-Generation Cephalosporin Plus Ciprofloxacin or Doxycycline Therapy in Patients with Vibrio vulnificus Septicemia: A Propensity Score-Matched Analysis.
    PLoS neglected tropical diseases, 2019, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Ciprofl

2019
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Disease Models,

2019
Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Blood; Camb

2013
Re: Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: E. O. Kehinde, M. Al-maghrebi, M. Sheikh and J. T. Anim J Urol 2013, 189: 911-915.
    The Journal of urology, 2013, Volume: 190, Issue:4

    Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost

2013
Neonatal meningitis and sepsis by Chryseobacterium indologenes: a rare and resistant bacterium.
    Indian journal of pediatrics, 2014, Volume: 81, Issue:6

    Topics: Anti-Bacterial Agents; Chryseobacterium; Ciprofloxacin; Drug Resistance, Bacterial; Female; Flavobac

2014
Reply by authors.
    The Journal of urology, 2013, Volume: 190, Issue:4

    Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost

2013
Reply by authors.
    The Journal of urology, 2014, Volume: 191, Issue:3

    Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost

2014
Re: combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate: O. Kehinde, M. Al-Maghrebi, M. Sheikh and J. T. Anim J Urol 2013; 189: 911–915.
    The Journal of urology, 2014, Volume: 191, Issue:3

    Topics: Amikacin; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Endosonography; Humans; Male; Prost

2014
Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Cancer, 2014, Apr-15, Volume: 120, Issue:8

    Topics: Adolescent; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Agents; Child; Child, Preschoo

2014
Cationic nanoemulsions bearing ciprofloxacin surf-plexes enhances its therapeutic efficacy in conditions of E. coli induced peritonitis and sepsis.
    Pharmaceutical research, 2014, Volume: 31, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Cations; Chitosan; Ciprofloxacin; Deoxycholic Acid; Drug Carriers; E

2014
Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate.
    BJU international, 2014, Volume: 113 Suppl 2

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis;

2014
In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Cefotaxime; Cell Death; Ciprofloxacin; Colony Coun

2014
Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK.
    BJU international, 2015, Volume: 116, Issue:1

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Drug Resistance, Bacteri

2015
Prophylactic antibiotics reduce sepsis after biopsy of the prostate.
    Danish medical journal, 2014, Volume: 61, Issue:11

    Topics: Aged; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Denmark; Drug Resistance, Bacterial; Hu

2014
Phage-mediated dispersal of biofilm and distribution of bacterial virulence genes is induced by quorum sensing.
    PLoS pathogens, 2015, Volume: 11, Issue:2

    Topics: Animals; Biofilms; Caco-2 Cells; Ciprofloxacin; Endocarditis, Bacterial; Enterococcus faecalis; Fema

2015
Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis.
    The Journal of urology, 2015, Volume: 194, Issue:2

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli; Escherichia

2015
Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host.
    Infectious disorders drug targets, 2015, Volume: 15, Issue:2

    Topics: Adult; Catheter-Related Infections; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Therapy, Co

2015
Successful Treatment of Chromobacterium violaceum Sepsis in a South Indian Adult.
    The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:5

    Topics: Abscess; Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Female; Humans; Imipenem; India; Mel

2015
Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Biopsy; Ceftriaxone; Ciprofloxacin;

2015
Reply by Authors.
    The Journal of urology, 2016, Volume: 195, Issue:1

    Topics: Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli Infections; Humans; Male; Prostate;

2016
Re: Comparative Effectiveness of Targeted vs Empirical Antibiotic Prophylaxis to Prevent Sepsis from Transrectal Prostate Biopsy: A Retrospective Analysis: M. A. Liss, W. Kim, D. Moskowitz and R. J. Szabo J Urol 2015;194:397-402.
    The Journal of urology, 2016, Volume: 195, Issue:1

    Topics: Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Escherichia coli Infections; Humans; Male; Prostate;

2016
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection.
    Journal of visualized experiments : JoVE, 2015, Sep-21, Issue:103

    Topics: Anti-Infective Agents, Local; Antibiotic Prophylaxis; Bacterial Infections; Biopsy, Needle; Ciproflo

2015
Septicemia Caused by Neisseria meningitidis With Decreased Ciprofloxacin Susceptibility: The First Case Report in Korea.
    Annals of laboratory medicine, 2016, Volume: 36, Issue:3

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftriaxone; Ciprofloxacin; Disk Diffusion Antimicrobial

2016
A case report of inhalation anthrax acquired naturally.
    BMC research notes, 2016, Mar-03, Volume: 9

    Topics: Aged; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Clindamycin; Fatal

2016
Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:6

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Ciprofloxacin; Criti

2016
Vibrio vulnificus infection and liver cirrhosis: a potentially lethal combination.
    BMJ case reports, 2016, May-05, Volume: 2016

    Topics: Adult; Animals; Ciprofloxacin; Debridement; Doxycycline; Early Diagnosis; Humans; Liver Cirrhosis; M

2016
The prevalence of urinary tract infection, or urosepsis following transrectal ultrasound-guided prostate biopsy in a subset of the Saudi population and patterns of susceptibility to flouroquinolones.
    Saudi medical journal, 2016, Volume: 37, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Cipro

2016
Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Chromosomes, Bacterial; Ciprofloxacin; Disease Models, Animal; Esche

2016
Opioid Dependent Malingerer with Self-Induced Sepsis.
    The western journal of emergency medicine, 2016, Volume: 17, Issue:6

    Topics: Analgesics, Opioid; Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Echinocandins; Emergenc

2016
Re: Combined Therapy with Adipose-Derived Mesenchymal Stem Cells and Ciprofloxacin against Acute Urogenital Organ Damage in Rat Sepsis Syndrome Induced by Intrapelvic Injection of Cecal Bacteria.
    The Journal of urology, 2016, Volume: 196, Issue:6

    Topics: Adipose Tissue; Adiposity; Animals; Bacteria; Ciprofloxacin; Disease Models, Animal; Humans; Mesench

2016
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
    The Journal of infection, 2008, Volume: 57, Issue:6

    Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Co

2008
[Two cases of Bacillus infection and immunodepression].
    Medecine et maladies infectieuses, 2008, Volume: 38, Issue:11

    Topics: Amoxicillin; Anti-Bacterial Agents; Bacillus; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Clav

2008
Antimicrobial resistance among Escherichia coli strains isolated from healthy and septicemic chickens.
    Pakistan journal of biological sciences : PJBS, 2007, Sep-01, Volume: 10, Issue:17

    Topics: Animals; Anti-Infective Agents; Bacteremia; Case-Control Studies; Chickens; Ciprofloxacin; Drug Resi

2007
Mycotic abdominal aortic aneurysm due to Streptococcus suis: a case report.
    Surgical infections, 2010, Volume: 11, Issue:2

    Topics: Aneurysm, Infected; Animals; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Arthritis, Infectiou

2010
Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin.
    Indian journal of medical sciences, 2009, Volume: 63, Issue:10

    Topics: Administration, Oral; Adult; Agranulocytosis; Anti-Bacterial Agents; Anti-Infective Agents; Ciproflo

2009
Severe systemic sepsis due to pyogenic liver abscess.
    Irish journal of medical science, 2012, Volume: 181, Issue:2

    Topics: Anti-Bacterial Agents; Ciprofloxacin; Fatal Outcome; Humans; Imipenem; Klebsiella Infections; Klebsi

2012
Ciprofloxacin prevents myelination delay in neonatal rats subjected to E. coli sepsis.
    Annals of neurology, 2011, Volume: 69, Issue:2

    Topics: Animals; Animals, Newborn; Anti-Infective Agents; Ciprofloxacin; Demyelinating Diseases; Escherichia

2011
An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis.
    Journal of biomedical nanotechnology, 2011, Volume: 7, Issue:1

    Topics: Animals; Anti-Infective Agents; Chitosan; Ciprofloxacin; Deoxycholic Acid; Drug Compounding; Lipopol

2011
In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:1

    Topics: Acinetobacter baumannii; Animals; Anti-Infective Agents; Biological Transport, Active; Cell Line; Ce

2012
Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.
    BJU international, 2012, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Biopsy, Needle; Ciprofloxacin; Emergencies; E

2012
[Neonatal infection with Stenotrophomonas maltophilia (2 case studies)].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2012, Volume: 19, Issue:4

    Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Chloramphenicol; Ciprofloxacin; Cross Infection; Dru

2012
Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?
    European urology, 2012, Volume: 62, Issue:3

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Chi-Square Distribution; Ciprof

2012
Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9

    Topics: Acetamides; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Routes; Drug Administ

2012
Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:4

    Topics: Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Util

2013
Cutaneous abscess leading to sepsis by Aeromonas hydrophila.
    Infection, 2013, Volume: 41, Issue:2

    Topics: Abscess; Aeromonas hydrophila; Cefepime; Cephalosporins; Ciprofloxacin; Fever; Gram-Negative Bacteri

2013
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
    Acta haematologica, 2013, Volume: 129, Issue:1

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Ciprofloxac

2013
Systemic exposure, tissue distribution, and disease evolution of a high solubility ciprofloxacin-aluminum complex in a murine model of septicemia induced by salmonella enterica serotype Enteritidis.
    Molecular pharmaceutics, 2013, Feb-04, Volume: 10, Issue:2

    Topics: Aluminum; Animals; Ciprofloxacin; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity

2013
The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey.
    BMC pediatrics, 2013, Jan-07, Volume: 13

    Topics: Anti-Infective Agents; Antifungal Agents; Ciprofloxacin; Drug Utilization; Fluconazole; Health Care

2013
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:8

    Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression;

2002
[Epidemiology of septicaemia pathogens].
    Deutsche medizinische Wochenschrift (1946), 2002, Nov-15, Volume: 127, Issue:46

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Austria; Bacteremia; Bacteria; Ciprofloxacin; Drug Res

2002
A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Feb-15, Volume: 36, Issue:4

    Topics: Anti-Infective Agents; Ciprofloxacin; Critical Illness; Gangrene; Humans; Male; Middle Aged; Sepsis;

2003
Patterns of mutations in target genes in septicemia isolates of Escherichia coli and Klebsiella pneumoniae with resistance or reduced susceptibility to ciprofloxacin.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2003, Volume: 111, Issue:9

    Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli;

2003
Extracranial mycotic carotid pseudoaneurysm.
    ANZ journal of surgery, 2003, Volume: 73, Issue:11

    Topics: Aneurysm, False; Aneurysm, Infected; Anti-Infective Agents; Carotid Artery Diseases; Carotid Artery,

2003
Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
    Shock (Augusta, Ga.), 2004, Volume: 21, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cecum; Ciprofloxacin; Clindamycin; Colony-For

2004
Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Male; Microbial Se

2004
Chryseobacterium meningosepticum infections in a dialysis unit.
    The Ceylon medical journal, 2004, Volume: 49, Issue:2

    Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Equipment Contamination; Flavobacteriaceae Infecti

2004
Multiple dose pharmacokinetics of ciprofloxacin in preterm babies.
    Indian pediatrics, 2004, Volume: 41, Issue:10

    Topics: Anti-Infective Agents; Birth Weight; Ciprofloxacin; Humans; Infant, Newborn; Infant, Premature; Infa

2004
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:10

    Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ec

2004
Safety profile of ciprofloxacin used for neonatal septicemia.
    Indian pediatrics, 2004, Volume: 41, Issue:12

    Topics: Anti-Infective Agents; Cartilage; Ciprofloxacin; Female; Humans; Infant, Newborn; Male; Sepsis; Ultr

2004
Chromobacterium violaceum septicaemia from north India.
    The Indian journal of medical research, 2004, Volume: 120, Issue:6

    Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Chromobacter

2004
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    International journal of antimicrobial agents, 2005, Volume: 25, Issue:2

    Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN

2005
Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis.
    International journal of antimicrobial agents, 2005, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Body Fluid Compartments; Ciprofloxac

2005
Effect of combination therapy with ciprofloxacin and azlocillin in intensive care patients with pneumonia and/or sepsis.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Anti-Bacterial Agents; Azlocillin; Bacteria; Ciprofloxacin; Clinical Trials as Topic; Critical Care;

1989
A rare cause of sepsis in an 18 year old. Lemierre's syndrome with external jugular vein thrombosis.
    Irish medical journal, 2006, Volume: 99, Issue:1

    Topics: Adolescent; Anti-Infective Agents; Body Piercing; Ciprofloxacin; Clindamycin; Diagnosis, Differentia

2006
Anterior surgery with insertion of titanium mesh cage and posterior instrumented fusion performed sequentially on the same day under one anesthesia for septic spondylitis of thoracolumbar spine: is the use of titanium mesh cages safe?
    Spine, 2006, Apr-20, Volume: 31, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Internal Fixat

2006
Ceftriaxone-resistant Salmonella septicemia and osteomyelitis in sickle cell disease adults.
    Southern medical journal, 2006, Volume: 99, Issue:6

    Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Ciprofloxacin

2006
One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study.
    BJU international, 2007, Volume: 99, Issue:2

    Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Nephrostomy, Percutaneous; Preoperative Care; Sensitiv

2007
Budvicia aquatica sepsis in an immunocompromised patient following exposure to the aftermath of Hurricane Katrina.
    Journal of medical microbiology, 2007, Volume: 56, Issue:Pt 8

    Topics: Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Disasters; Enterobacteriaceae; Enterobacter

2007
Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2007, Volume: 13, Issue:4

    Topics: Animals; Carboxypeptidase B2; Ciprofloxacin; Enterococcus faecalis; Gram-Negative Bacterial Infectio

2007
Salmonella-a new threat to neonates.
    Mymensingh medical journal : MMJ, 2007, Volume: 16, Issue:2 Suppl

    Topics: Bangladesh; Ciprofloxacin; Cross-Sectional Studies; Female; Humans; Imipenem; Infant, Newborn; Male;

2007
Optimizing use of ciprofloxacin: a prospective intervention study.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Prescriptions; Drug Resis

2008
Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction.
    Intensive care medicine, 2008, Volume: 34, Issue:5

    Topics: Animals; Ciprofloxacin; Endothelin-1; Female; Hypertension, Pulmonary; Lipopolysaccharides; Lung; Ma

2008
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
    The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:6

    Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle

1995
[Sepsis and spondylodiscitis caused by Salmonella enteritidis].
    Deutsche medizinische Wochenschrift (1946), 1993, Dec-17, Volume: 118, Issue:50

    Topics: Ciprofloxacin; Discitis; Drug Administration Schedule; Humans; Male; Middle Aged; Radiography; Salmo

1993
Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis.
    Critical care medicine, 1997, Volume: 25, Issue:8

    Topics: Anti-Infective Agents; Cell Line; Ciprofloxacin; Drug Evaluation, Preclinical; Endothelium, Vascular

1997
The relationship between the use of flucloxacillin, vancomycin, aminoglycosides and ciprofloxacin and the susceptibility patterns of coagulase-negative staphylococci recovered from blood cultures.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:5

    Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Coagul

1997
Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity.
    Shock (Augusta, Ga.), 1998, Volume: 10, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Body Temperature; Cecum; Ciprofloxacin; Clindamycin; Cytokines; Drug

1998
Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:9

    Topics: Adult; Animals; Anti-Infective Agents; Ciprofloxacin; Humans; Injections, Intravenous; Metabolic Cle

1998
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
    The Journal of infectious diseases, 1998, Volume: 178, Issue:4

    Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Com

1998
Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin.
    Journal of perinatology : official journal of the California Perinatal Association, 1999, Volume: 19, Issue:4

    Topics: Age of Onset; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple; Drug Therapy, Combina

1999
Successful treatment of an infant with Chromobacterium violaceum sepsis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Mar-15, Volume: 32, Issue:6

    Topics: Anti-Bacterial Agents; Chromobacterium; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; H

2001
Aeromonas sobria sepsis in a neutropenic patient.
    Haematologica, 2001, Volume: 86, Issue:4

    Topics: Acute Disease; Aeromonas; Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxaci

2001
Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
    Intensive care medicine, 2002, Volume: 28, Issue:4

    Topics: Anti-Infective Agents; Child, Preschool; Ciprofloxacin; Female; Humans; Infant; Injections, Intraven

2002
Antibiotic susceptibility pattern of Salmonella worthington isolated from neonates--a retrospective study.
    Japanese journal of infectious diseases, 2002, Volume: 55, Issue:2

    Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Chloramphenicol; Ciprofloxacin;

2002
Salmonella, Campylobacter and Shigella in HIV-seropositive patients.
    AIDS (London, England), 1992, Volume: 6, Issue:12

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Campylobacter Infections; CD4-Positive T-Lymphoc

1992
Successful treatment of Bacillus cereus infection with ciprofloxacin.
    Thorax, 1991, Volume: 46, Issue:3

    Topics: Adult; Bacillus cereus; Ciprofloxacin; Humans; Male; Pneumonia; Sepsis

1991
Oral antibiotic prophylaxis in patients with hematological diseases.
    Scandinavian journal of infectious diseases, 1991, Volume: 23, Issue:4

    Topics: Ciprofloxacin; Humans; Norfloxacin; Sepsis; Staphylococcal Infections

1991
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
    The Journal of infectious diseases, 1991, Volume: 163, Issue:2

    Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe

1991
Septicaemia caused by an imported strain of multiply antibiotic resistant Salmonella typhi successfully treated with ciprofloxacin.
    Tropical and geographical medicine, 1990, Volume: 42, Issue:4

    Topics: Ciprofloxacin; Drug Resistance, Microbial; Feces; Humans; India; Male; Middle Aged; Recurrence; Salm

1990
Splenic and renal abscesses following Salmonella virchow septicaemia--conservative management with ciprofloxacin.
    The British journal of clinical practice, 1990, Volume: 44, Issue:12

    Topics: Abscess; Adult; Ciprofloxacin; Female; Humans; Kidney Diseases; Salmonella Infections; Sepsis; Splen

1990
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1990, Volume: 9, Issue:4

    Topics: Amikacin; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Enterobacteriaceae;

1990
Reversible leukopenia related to ciprofloxacin therapy.
    Southern medical journal, 1990, Volume: 83, Issue:5

    Topics: Ciprofloxacin; Endocarditis, Bacterial; Female; Heart Valve Prosthesis; Humans; Leukopenia; Middle A

1990
Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.
    The Journal of infectious diseases, 1990, Volume: 161, Issue:1

    Topics: Aged; Ciprofloxacin; Coagulase; Drug Resistance, Microbial; Female; Humans; Immune Tolerance; Leukem

1990
Prevention of bacteremias caused by alpha-hemolytic streptococci by roxithromycin in patients treated with intensive cytotoxic treatment.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Acute Disease; Adult; Agranulocytosis; Amphotericin B; Antineoplastic Combined Chemotherapy Protocol

1990
Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.
    European journal of clinical microbiology, 1986, Volume: 5, Issue:2

    Topics: Administration, Oral; Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Postoperative Compli

1986
[Ciprofloxacin: a solution for recurrent bacteremia caused by Salmonella non typhi in acquired immunodeficiency syndrome?].
    Enfermedades infecciosas y microbiologia clinica, 1989, Volume: 7, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Ciprofloxacin; Humans; Male; Middle Aged; Recurrence; Salmonella

1989
Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit.
    BMJ (Clinical research ed.), 1989, Jul-29, Volume: 299, Issue:6694

    Topics: Cancer Care Facilities; Ciprofloxacin; Coagulase; Cross Infection; Disease Outbreaks; Drug Resistanc

1989
Successful treatment with ciprofloxacin of multiresistant salmonella arthritis in a renal transplant recipient.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1989, Volume: 4, Issue:5

    Topics: Arthritis, Infectious; Ciprofloxacin; Drug Resistance, Microbial; Female; Hip Joint; Humans; Opportu

1989
Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989, Volume: 8, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Ge

1989
Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
    The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Ciprofloxacin; Female; H

1989
Intravenous and oral ciprofloxacin treatment of 52 infections.
    The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A

    Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Female; Humans; Infusions, Intravenous; M

1989
Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
    The American journal of medicine, 1989, Nov-30, Volume: 87, Issue:5A

    Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male;

1989
Ciprofloxacin in neonatal Enterobacter cloacae septicaemia.
    Archives of disease in childhood, 1989, Volume: 64, Issue:10 Spec No

    Topics: Ciprofloxacin; Enterobacter; Enterobacteriaceae Infections; Humans; Infant, Newborn; Infant, Prematu

1989
Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia.
    The Netherlands journal of medicine, 1989, Volume: 35, Issue:3-4

    Topics: Adult; Agranulocytosis; Amsacrine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Proto

1989
Ciprofloxacin for Salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS).
    Annals of internal medicine, 1989, Jun-15, Volume: 110, Issue:12

    Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Humans; Male; Middle Aged; Recurrence; Sal

1989
Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.
    Antimicrobial agents and chemotherapy, 1989, Volume: 33, Issue:2

    Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Female; Imipenem;

1989
[A case report of septicemia caused by methicillin cephem resistant Staphylococcus aureus (MRSA)].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1989, Volume: 80, Issue:5

    Topics: Ciprofloxacin; Female; Humans; Methicillin; Middle Aged; Penicillin Resistance; Sepsis; Staphylococc

1989
Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.
    The American journal of medicine, 1989, Volume: 87, Issue:4

    Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumonia, Pneumococcal; Sepsis

1989
Open, prospective study of the clinical efficacy of ciprofloxacin.
    Antimicrobial agents and chemotherapy, 1985, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Arthritis; Bacterial Infections; Ciprofloxacin; Female; Gastrointestinal Di

1985
Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin.
    The Journal of antimicrobial chemotherapy, 1985, Volume: 16, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Drug Resistance, Microbial; Hu

1985
Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a splenectomized and immunosuppressed patient.
    The Journal of antimicrobial chemotherapy, 1988, Volume: 21, Issue:6

    Topics: Adult; Ciprofloxacin; Humans; Immunosuppression Therapy; Male; Salmonella Infections; Salmonella typ

1988
Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.
    Journal of the Royal Society of Medicine, 1987, Volume: 80, Issue:5

    Topics: Adolescent; Aged; Agranulocytosis; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial;

1987
Enterococcal superinfection in patients treated with ciprofloxacin.
    The Journal of antimicrobial chemotherapy, 1988, Volume: 21, Issue:1

    Topics: Adult; Aged; Ciprofloxacin; Enterococcus faecalis; Humans; Kidney Failure, Chronic; Male; Pseudomona

1988
Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.
    The American journal of medicine, 1988, Volume: 84, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Administration Schedule; E

1988
Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.
    Infection, 1988, Volume: 16, Issue:1

    Topics: Agranulocytosis; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combinat

1988
Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.
    Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:11

    Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Female; Klebsiella Infections; Kl

1987
Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.
    Pharmaceutisch weekblad. Scientific edition, 1987, Dec-11, Volume: 9 Suppl

    Topics: Animals; Ceftazidime; Ciprofloxacin; Drug Administration Schedule; Klebsiella Infections; Klebsiella

1987
Ciprofloxacin: initial evaluation in immunocompromised patients.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987, Volume: 6, Issue:2 Suppl

    Topics: Antineoplastic Agents; Bacterial Infections; Bone Marrow Transplantation; Ciprofloxacin; Humans; Imm

1987
In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
    Chemotherapy, 1987, Volume: 33, Issue:6

    Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative

1987
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.
    The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl D

    Topics: Adult; Aged; Agranulocytosis; Bacterial Infections; Ciprofloxacin; Female; Fever; Half-Life; Humans;

1986
Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a patient with acquired immune deficiency syndrome.
    The Journal of antimicrobial chemotherapy, 1986, Volume: 18, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Humans; Male; Recurrence; Salmonella Infec

1986
Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:4

    Topics: Animals; Ciprofloxacin; Drug Evaluation, Preclinical; Endocarditis, Bacterial; Kinetics; Methicillin

1987
Dosage of intravenous ciprofloxacin.
    The Journal of antimicrobial chemotherapy, 1987, Volume: 20, Issue:3

    Topics: Acute Kidney Injury; Adult; Ciprofloxacin; Humans; Injections, Intravenous; Male; Pseudomonas Infect

1987
Comparative in vitro activity of ciprofloxacin and other antimicrobial agents against aminoglycoside-resistant gram-negative rods and microorganisms isolated from patients with bacteremia.
    Chemotherapy, 1986, Volume: 32, Issue:5

    Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Gram-Negative Bac

1986
Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.
    The Journal of infectious diseases, 1987, Volume: 155, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Clofazimine; Cyc

1987